Renexxion Ireland Limited is a pharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (GI) disorders with its pipeline in a pill: naronapride.
Naronapride is a late-development stage, pan-GI prokinetic. It is a highly selective 5HT-4 agonist and D2 antagonist, both validated targets for GI motility. Naronapride has been designed to be minimally absorbed, avoiding systemic effects and acting locally in the gut lumen.
It is estimated that at least 16% of people worldwide are affected by GI-related disorders. Currently approved therapies do not completely address the high therapeutic need. Naronapride has the potential to address the major GI indications including PPI non-responsive gastro-esophageal reflux disease (GERD), gastroparesis, chronic idiopathic constipation (CIC), irritable bowel syndrome- constipation (IBS-C), functional dyspepsia (FD) and GI dysmotility in Cystic Fibrosis.
Naronapride is being developed for PPI non-responsive GERD and gastroparesis. (More...)